Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 3
2006 9
2007 9
2008 21
2009 29
2010 31
2011 48
2012 74
2013 81
2014 71
2015 104
2016 120
2017 114
2018 101
2019 89
2020 86
2021 14
Text availability
Article attribute
Article type
Publication date

Search Results

881 results
Results by year
Filters applied: . Clear all
Page 1
Clinical Pharmacokinetics and Pharmacodynamics of Panobinostat.
Van Veggel M, Westerman E, Hamberg P. Van Veggel M, et al. Clin Pharmacokinet. 2018 Jan;57(1):21-29. doi: 10.1007/s40262-017-0565-x. Clin Pharmacokinet. 2018. PMID: 28667459 Review.
The absolute bioavailability of panobinostat is 21.4%, and it is moderately bound to plasma proteins. ...Panobinostat itself is a CYP2D6 inhibitor, which influences the plasma levels of the CYP2D6 substrate dexamethasone. ...
The absolute bioavailability of panobinostat is 21.4%, and it is moderately bound to plasma proteins. ...Panobinostat itself i …
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Günther A, Nakorn TN, Siritanaratkul N, Corradini P, Chuncharunee S, Lee JJ, Schlossman RL, Shelekhova T, Yong K, Tan D, Numbenjapon T, Cavenagh JD, Hou J, LeBlanc R, Nahi H, Qiu L, Salwender H, Pulini S, Moreau P, Warzocha K, White D, Bladé J, Chen W, de la Rubia J, Gimsing P, Lonial S, Kaufman JL, Ocio EM, Veskovski L, Sohn SK, Wang MC, Lee JH, Einsele H, Sopala M, Corrado C, Bengoudifa BR, Binlich F, Richardson PG. San-Miguel JF, et al. Lancet Oncol. 2014 Oct;15(11):1195-206. doi: 10.1016/S1470-2045(14)70440-1. Epub 2014 Sep 18. Lancet Oncol. 2014. PMID: 25242045 Clinical Trial.
Minimal responses were noted in 23 (6%) patients in the panobinostat group and in 42 (11%) in the placebo group. Median duration of response (partial response or better) was 1314 months (95% CI 1176-1492) in the panobinostat group and 1087 months (923-1176) in the p …
Minimal responses were noted in 23 (6%) patients in the panobinostat group and in 42 (11%) in the placebo group. Median duration of r …
Panobinostat and Multiple Myeloma in 2018.
Yee AJ, Raje NS. Yee AJ, et al. Oncologist. 2018 May;23(5):516-517. doi: 10.1634/theoncologist.2017-0644. Epub 2018 Feb 14. Oncologist. 2018. PMID: 29445026 Free PMC article.
FDA and EMA approval of panobinostat offers an additional therapeutic option for multiple myeloma; however, adoption of panobinostat has been limited by its adverse event profile. Trials are ongoing to optimize the dosing of panobinostat and to identify its b …
FDA and EMA approval of panobinostat offers an additional therapeutic option for multiple myeloma; however, adoption of panobinost
panobinostat (FARYDAK). Multiple myeloma: too toxic!
[No authors listed] [No authors listed] Prescrire Int. 2016 Nov;25(176):257-259. Prescrire Int. 2016. PMID: 30715819 Review.
Panobinostat did not prolong survival. The median time to myeloma progression, relapse, or death was prolonged by about 3 months with the panobinostat-containing combination, and by a median of about 8 months in the subgroup of patients who had received at least two
Panobinostat did not prolong survival. The median time to myeloma progression, relapse, or death was prolonged by about 3 months with
Panobinostat: first global approval.
Garnock-Jones KP. Garnock-Jones KP. Drugs. 2015 Apr;75(6):695-704. doi: 10.1007/s40265-015-0388-8. Drugs. 2015. PMID: 25837990 Review.
Panobinostat is in various stages of clinical development worldwide for a range of haematological and solid tumours. This article summarizes the milestones in the development of panobinostat leading to this first approval for multiple myeloma....
Panobinostat is in various stages of clinical development worldwide for a range of haematological and solid tumours. This article sum
Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment.
Richardson PG, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Guenther A, Nakorn TN, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa BR, Corrado C, Binlich F, San-Miguel JF. Richardson PG, et al. Blood. 2016 Feb 11;127(6):713-21. doi: 10.1182/blood-2015-09-665018. Epub 2015 Dec 2. Blood. 2016. PMID: 26631116 Free PMC article. Clinical Trial.
Panobinostat is a potent pan-deacetylase inhibitor that affects the growth and survival of multiple myeloma (MM) cells through alteration of epigenetic mechanisms and protein metabolism. Panobinostat plus bortezomib and dexamethasone (PAN-BTZ-Dex) led to a significa
Panobinostat is a potent pan-deacetylase inhibitor that affects the growth and survival of multiple myeloma (MM) cells through altera
Panobinostat for the Treatment of Multiple Myeloma.
Laubach JP, Moreau P, San-Miguel JF, Richardson PG. Laubach JP, et al. Clin Cancer Res. 2015 Nov 1;21(21):4767-73. doi: 10.1158/1078-0432.CCR-15-0530. Epub 2015 Sep 11. Clin Cancer Res. 2015. PMID: 26362997 Free article. Review.
Panobinostat is a potent oral deacetylase inhibitor that alters gene expression through epigenetic mechanisms and inhibits protein degradation. ...Additional ongoing trials are evaluating panobinostat in combination with other partners in the relapsed/refractory and
Panobinostat is a potent oral deacetylase inhibitor that alters gene expression through epigenetic mechanisms and inhibits protein de
Panobinostat (LBH589) inhibits Wnt/beta-catenin signaling pathway via upregulating APCL expression in breast cancer.
Qin G, Li Y, Xu X, Wang X, Zhang K, Tang Y, Qiu H, Shi D, Zhang C, Long Q, Lee K, Zhai Q, Wang S, Chen M, Deng W. Qin G, et al. Cell Signal. 2019 Jul;59:62-75. doi: 10.1016/j.cellsig.2019.03.014. Epub 2019 Mar 14. Cell Signal. 2019. PMID: 30880222
In consideration of the transcription promoting activity of panobinostat, we speculated that specific tumor suppressor genes might be upregulated after panobinostat treatment. ...Consistently, panobinostat inhibited breast cancer growth and metastasis in mous …
In consideration of the transcription promoting activity of panobinostat, we speculated that specific tumor suppressor genes might be …
EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma.
Tzogani K, van Hennik P, Walsh I, De Graeff P, Folin A, Sjöberg J, Salmonson T, Bergh J, Laane E, Ludwig H, Gisselbrecht C, Pignatti F. Tzogani K, et al. Oncologist. 2018 May;23(5):631-636. doi: 10.1634/theoncologist.2017-0301. Epub 2017 Nov 30. Oncologist. 2018. PMID: 29192015 Free PMC article. Review.
On August 28, 2015, a marketing authorization valid through the European Union was issued for panobinostat, in combination with bortezomib and dexamethasone, for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two …
On August 28, 2015, a marketing authorization valid through the European Union was issued for panobinostat, in combination with borte …
Panobinostat and venetoclax enhance the cytotoxicity of gemcitabine, busulfan, and melphalan in multiple myeloma cells.
Valdez BC, Li Y, Murray D, Liu Y, Nieto Y, Bashir Q, Qazilbash MH, Andersson BS. Valdez BC, et al. Exp Hematol. 2020 Jan;81:32-41. doi: 10.1016/j.exphem.2020.01.003. Epub 2020 Jan 15. Exp Hematol. 2020. PMID: 31954171 Free PMC article.
To further improve their efficacy, a preclinical study on their synergism with the histone deacetylase inhibitor panobinostat (Pano) and the BCL2 inhibitor venetoclax/ABT199 was performed. ...
To further improve their efficacy, a preclinical study on their synergism with the histone deacetylase inhibitor panobinostat (Pano) …
881 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page